Shifting gears from $1,000 genome to big data analytics

The $1,000 genome was a worthy cause that helped motivate scientists and engineers to drive down the cost of decoding DNA, but now there are numerous steps needed to analyze the data from sequenced genomes to deliver personalized care for patients with cancer and other diseases. In a summary of key messages from Harvard Medical School's Mark Boguski, Forbes contributor Jim Golden wrote that "the time of the $1,000 genome meme is over," and the real value of genomics for patients with cancer is an ongoing analysis of their disease using big data tools. To deliver such analysis for patient treatment, Boguski is working on a new company called Genomic Health Solutions. Item

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

The $58 million financing round represents biopharma industry's growing interest in genomics data.

Clinerion inks a new deal that adds 60 million U.S. patients to its clinical trial patient recruitment system.